Aderbasib

Aderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large B-cell non-Hodgkin lymphoma, HER2+ breast cancer, gliomas, et al[1].

Product Specifications

CAS Number

[791828-58-5]

Product Name Alternative

INCB007839; INCB7839

UNSPSC

12352005

Target

MMP

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/aderbasib.html

Purity

99.44

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N(CC1)CCN1C2=CC=CC=C2)[C@H]([C@H](C3)C(NO)=O)N(CC43CC4)C(OC)=O

Molecular Formula

C21H28N4O5

Molecular Weight

416.47

References & Citations

[1]Lois Witters, et al. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res. 2008 Sep 1;68 (17) :7083-9.|[2]Fei Yuan, et al. ADAM17 is an essential attachment factor for classical swine fever virus. PLoS Pathog. 2021 Mar 8;17 (3) :e1009393.